New drug shows promising results in recovery of patients after heart attack
最近審查：14.06.2024
所有iLive內容都經過醫學審查或事實檢查，以確保盡可能多的事實準確性。
我們有嚴格的採購指南，只鏈接到信譽良好的媒體網站，學術研究機構，並儘可能與醫學同行評審的研究相關聯。 請注意括號中的數字（[1]，[2]等）是這些研究的可點擊鏈接。
如果您認為我們的任何內容不准確，已過時或有疑問，請選擇它並按Ctrl + Enter。
Researchers from the Cardiac Regeneration and Heart Failure Research Group (ICREC) at the Instituto de Recherche Germáns Trias i Pujol (IGTP) and the Heart Institute of the Germans Trias Hospital (iCor) have discovered beneficial effects of the new drug Sacubitril/Valsartan in the treatment of heart attack myocardial infarction.
Their study, recently published in the journal Circulation: Arrhythmia and Electrophysiology, offers new insights into the drug's ability to reduce inflammation, cardiac fibrosis, and prevent dangerous cardiac arrhythmias after myocardial infarction.
Cardiovascular disease, especially myocardial infarction, is the leading cause of death worldwide. Following such an event, the damaged myocardium, which has suffered from ischemia, mounts an intense inflammatory response to remove dead cells and activate the replacement of necrotic tissue with a collagen scar.
While the scar maintains the structural integrity of the heart, it does not contribute to the heart's pumping function and increases the risk of malignant arrhythmias, which contributes to the development of heart failure, a condition in which the heart cannot pump blood effectively to meet the body's needs.
In this context, Sacubitril/Valsartan is a combination drug that has shown promising results in reducing rehospitalizations and cardiovascular mortality in patients with heart failure. While the role of this drug in the treatment of heart failure is beginning to be well established, its effectiveness in the management of myocardial infarction remains largely unexplored. In this regard, the present study aimed to evaluate the effects of early administration of Sacubitril/Valsartan in a preclinical porcine model of myocardial infarction in terms of inflammation, cardiac fibrosis and arrhythmogenic properties of the heart.
The drug has shown promising results in mitigating these effects, reducing acute systemic inflammatory response and the risk of fatal arrhythmias by 55%, and promoting healthier scar formation. Drs Felipe Bisbal and Carolina Galvez-Monton, who led the study, said that "the effects of Sacubitril/Valsartan in a porcine model of myocardial infarction are very promising and suggest that this new drug may significantly improve the prognosis and quality of life of patients suffering from this event.".
Future human clinical evaluation studies will be key to determining the reproducibility of these findings and the clinical benefit of Sacubitril/Valsartan therapy in the myocardial infarction scenario.